ClinicalTrials.gg
RecruitingNCT06148883MONITORTAVIUpdated Jul 1, 2025

Management of Patients With New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

An interventional study of Transcatheter Aortic Valve Implantation in Left Bundle-Branch Block, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to show that Electrocardiogram Ambulatory Monitoring-guided strategy is superior to ElectroPhysiological Study on the rate of alive patients with an appropriate Pacemaker implantation/non-implantation, at 12 months after randomization, in patients with New Onset Persistent Left Bundle Branch Block after Transcatheter Aortic Valve Implantation.

Read the detailed description

This is a prospective, multicentric, randomized in parallel group, controlled, open labelled clinical study.

  • After Transcatheter Aortic Valve Implantation, all consecutive patients presenting with new onset Left Bundle Branch Block will undergo in-hospital telemetry. In case of persistence (at least 48 hours) of a stable (i.e., no change in the last 24 hours) Left Bundle Branch Block > 150 ms, and in the absence of high grade Aortic Valve block or persistent prolonged PR interval > 240 ms, patients will be eligible for the study
  • After written consent will be obtained, included patients will be randomized into two groups according to a 1:1 ratio:

    • Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge. In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring. Any other clinically relevant therapeutic decision based on Electrocardiogram Ambulatory Monitoring will be taken or
    • ElectroPhysiological Study for infra-hisian conduction evaluation. Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms
  • Patients in both groups will be followed until the end of the first year after randomization. Follow-up visits will be scheduled in person at 1 and 12 months, and through telemedicine at 3 and 6 months. Appropriateness of Pacemaker implantation/non-implantation will be evaluated at each follow-up time
  • In case of any occurrence of syncope, patients will be evaluated in person, by the principal investigator of each centre, to evaluate and manage the syncope as recommended by the European Society of Cardiology guidelines.

Patients will be followed-up according to current practice.

02

Conditions studied

  • Left Bundle-Branch Block

Browse trials for

03

In context

Bundle-Branch Block

94 studies on the registry are indexed under Bundle-Branch Block; 30 are open to participants now.

This study's planned enrollment of 360 is above the median of 60 across 59 interventional studies indexed under Bundle-Branch Block.

Browse Bundle-Branch Block studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who are 18 years or older and undergo Transcatheter Aortic Valve Implantation :

  1. Presenting with New Onset Persistent Left Bundle Branch Block, defined as a new Left Bundle Branch Block >150 ms that persists at least two days after Transcatheter Aortic Valve Implantation and is stable
  2. With an anticipated >1 year
  3. Who consent to participate to the study

Exclusion criteria

Exclusion Criteria:

  1. During in-hospital monitoring period, immediately after Transcatheter Aortic Valve Implantation and before inclusion:

    • Documented high grade Atrio Ventricular block (Atrio Ventricular block of a degree higher than Mobitz I)
    • Persistent PR interval prolongation > 240 ms
    • Occurrence of syncope or sudden cardiac death,
    • Identification of any indisputable criteria for Pacemaker implantation
    • Definitive Pacemaker implantation
  2. Prior Pacemaker or Implantable Cardiac defibrillator
  3. Indication for Cardiac Resynchronization Therapy or Implantable cardiac defibrillator
  4. Pre-existing Left Bundle Branch Block or Right Bundle Branch Block
  5. Pre-existing PR interval prolongation > 240 ms
  6. Severe or moderate dementia, evaluated before Transcatheter Aortic Valve Implantation, defined as a \< 15
  7. Pregnancy or breastfeeding patient
  8. No affiliation to a social security scheme
  9. Adult under legal protection (trusteeship, guardianship).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge

    In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring.

    Procedure: Transcatheter Aortic Valve Implantation

  • Experimental
    Electrocardiogram Ambulatory Monitoring for infra-hisian conduction evaluation

    In this group, Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms.

    Procedure: Transcatheter Aortic Valve Implantation

Interventions

  • ProcedureTranscatheter Aortic Valve Implantation

    Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously

06

What researchers measure

Primary outcomes

  1. Alive status with appropriate Pacemaker implantation/non-implantation

    The primary endpoint of this study is the alive status with appropriate Pacemaker implantation/non-implantation, at 12 months after randomization. * Appropriate Pacemaker non-implantation: \- Absence of syncope or sudden cardiac death in a non-implanted patient * Appropriate Pacemaker implantation: * Documented indisputable criteria for Pacemaker implantation * Absence of syncope or sudden cardiac death * Absence of upgrading procedure

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

Of 32 interventional studies with no phase under Bundle-Branch Block, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 28, 2023
StartActual
Nov 12, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06148883
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Nov 12, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Baptiste MAILLE, MD
Contact
baptiste.maille@ap-hm.fr
491386576 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion